Con Dividere

Main Menu

  • Normal Value
  • Quota By Country
  • Statement of Financial Accounting
  • York Antwerp Rules
  • Commerce

Con Dividere

Header Banner

Con Dividere

  • Normal Value
  • Quota By Country
  • Statement of Financial Accounting
  • York Antwerp Rules
  • Commerce
Normal Value
Home›Normal Value›NeuroMetrix Submits De Novo Application to FDA for Treatment of Symptoms of Fibromyalgia with Quell

NeuroMetrix Submits De Novo Application to FDA for Treatment of Symptoms of Fibromyalgia with Quell

By Thomas Heikkinen
October 7, 2021
0
0

(RTTNews) – NeuroMetrix Inc. (NURO) said it has submitted a De Novo application to the United States Food and Drug Administration for a Quell wearable neuromodulation device as a prescription treatment for fibromyalgia symptoms in patients. adult. The company received breakthrough designation from the FDA for this indication in July.

NURO closed Wednesday’s regular trading at $ 8.62 down $ 0.76 or 8.10%. But in after-hours trading, the stock gained $ 1.23 or 14.27%.

The company hopes to commercially launch Quell for this indication in the second half of 2022.

Fibromyalgia is chronic pain that is accompanied by fatigue, sleep, cognitive and mood disturbances. The cause of fibromyalgia remains unclear, but scientific studies indicate abnormalities in the way the brain processes normal pain and sensation. There are currently no medical devices with FDA clearance or approval for the treatment of fibromyalgia.

The De Novo route for marketing authorization is available for low to moderate risk medical devices that do not have an authorized predicate device and are therefore not eligible for the pre-marketing notification process. market (i.e. 510 (k)).

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Source link

Related posts:

  1. It’s Time to Rethink Your Global Logistics
  2. Xtra-Gold Sources Pronounces 2021 Regular Course Tender Provide and 2020 Provide Outcomes
  3. The brand new assortment from Payal Singhal is brilliant, daring and primarily based on the brand new commonplace
  4. 2021 Lexus ES250 AWD First Take a look at: Accessible Luxurious
Tagsunited states

Recent Posts

  • FENNEC PHARMACEUTICALS INC. Management report and analysis of the financial situation and operating results. (Form 10-Q)
  • Stocks rebound after inflation moderates slightly, giving investors hope that prices may have peaked
  • Shipping industry reports 54 losses in 2021 amid challenges: Allianz
  • Once-Abundant Atlantic Cod Trait Hits New Low
  • Metro Bus restores express lanes and adds free service to parks | Local News

Archives

  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • March 2020
  • April 2019
  • June 2018
  • May 2018
  • June 2016
  • May 2016
  • November 2015

Categories

  • Commerce
  • Normal Value
  • Quota By Country
  • Statement of Financial Accounting
  • York Antwerp Rules
  • Terms and Conditions
  • Privacy Policy